Inhibrx Biosciences is a clinical-stage biopharmaceutical company that develops novel biologic therapeutics using proprietary single domain antibody and multispecific protein engineering platforms. The company's pipeline centers on two lead programs: ozekibart, a death receptor 5 agonist for oncology indications including chondrosarcoma and Ewing sarcoma, and INBRX-106, an OX40 agonist in development for solid tumors. As a pre-revenue company, Inhibrx plans to commercialize approved candidates through internal capabilities and partnerships, relying on a team with expertise in discovery, manufacturing, clinical development, and commercialization to bring therapeutics targeting serious cancers with significant unmet medical needs to market.